Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synergo RITE plus mitomycin C in BCG-refractory CIS NMIBC
2016-000049-30Phase 3Terminated
- Sponsor
- Medical Enterprises Europe
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mitomycin c in Bladder cancer in situ (CIS) and non-muscle-invasive bladder cancer (NMIBC), sponsored by Medical Enterprises Europe. Primary endpoint: Time to event. Started Jun 2017; status: terminated.
02
Drugs
mitomycin c
03
Conditions
Bladder cancer in situ (CIS)non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2016-000049-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000049-30.